Open house Trazodone Discount Contracts
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Trazodon, ATC N06AX05
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No minimum purchase commitment; expected volumes are not disclosed. Revenue from this contract is uncertain.
Contract can be automatically superseded if AOK closes a separate exclusive discount contract for the same substance vi...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Supply of Trazodone (ATC N06AX05) pharmaceutical products under non-exclusive discount agreements.
- Framework agreement with multiple pharmaceutical companies; no exclusivity.
Afficher le résumé complet
Open-house non-exclusive framework agreement for discount contracts on Trazodone (ATC N06AX05) by AOK Bayern. All qualified pharmaceutical companies may join. No competitive selection; contracts are non-negotiable. Duration 01.06.2025-31.05.2027. Rolling monthly enrollment. No estimated value provided. Eligibility: signed self-declaration of reliability. Submission in paper (2 copies) or electronic with qualified signature. Language: German. No procurement documents analyzed.
Risques
No minimum purchase commitment; expected volumes are not disclosed. Revenue from this contract is uncertain.
Contract can be automatically superseded if AOK closes a separate exclusive discount contract for the same substance vi...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Eligibility
- Only pharmaceutical companies are eligible.
Administrative
- Submission of signed contract, signed annex listing specific drugs, and signed self-declaration of reliability.
- Documents must be in German (translations required if originally in other languages).
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open house Trazodone Discount Contracts
One lot covering all Trazodone (ATC N06AX05) pharmaceutical products. Non-exclusive framework. All qualified companies can join.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
No award criteria
this is an open-house model where all qualified participants are accepted.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Trazodon, ATC N06AX05
Description TED originale
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Détails de la procédure
- Date de publication
- 15 Apr 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 250553-2025
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No minimum purchase commitment; expected volumes are not disclosed. Revenue from this contract is uncertain.
Contract can be automatically superseded if AOK closes a separate exclusive discount contract for the same substance vi...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications